Dataset Information

Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea.

ABSTRACT:

Background/aims

We examined the concordance rate among fasting plasma glucose (FPG), 2-hour post-challenge glucose (2hr PG), and hemoglobin A1c (HbA1c) in the diagnosis of diabetes in a population with a high-risk for type 2 diabetes mellitus (T2DM) in Korea.

Methods

Among the participants from the Korean Diabetes Prevention Study, individuals with FPG ≥ 100 mg/dL, body mass index (BMI) ≥ 23.0 kg/m2, and no previous history of T2DM were consecutively enrolled after a 75 g glucose tolerance test. We analyzed the differences in the clinical characteristics in subjects with stage 1 (FPG, 100 to 109 mg/dL) and stage 2 (FPG, 110 to 125 mg/dL) impaired fasting glucose (IFG).

Results

Of 1,637 participants, 27.2% had T2DM and 59.3% had IFG and/or impaired glucose tolerance (IGT). The mean age was 55.0 ± 8.1 years and the mean BMI was 26.3 ± 2.7 kg/m2. Based on FPG criteria, 515 (31.4%) and 352 (21.5%) subjects were classified as having stage 1 and stage 2 IFG, respectively. The 19.0% of stage 1 and 43.5% of stage 2 subjects showed 2hr PG levels in the diabetic range. Even for those in the normal FPG range, 63 (9.5%) participants showed a 2hr PG level of ≥ 200 mg/dL. Of 446 subjects with newly-diagnosed diabetes, 340 (76.2%) showed FPG levels < 126 mg/dL.

Conclusion

The oral glucose tolerance test should be actively considered for Korean adults who are overweight or obese with the IFG range (FPG, 100 to 125 mg/ dL) to allow for early detection of diabetes and prompt intervention.

SUBMITTER: Lee JH

PROVIDER: S-EPMC7969057 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BACKGOUND:Theobromine, a component of cocoa, may favorably affect conventional lipid-related cardiovascular risk markers, but effects on flow-mediated dilation (FMD) and other vascular function markers are not known. OBJECTIVE:To evaluate the effects of 4-week theobromine consumption (500 mg/day) on fasting and postprandial vascular function markers. DESIGN:In a randomized, double-blind crossover study, 44 apparently healthy overweight (N?=?30) and obese (N?=?14) men and women with low HDL-C concentrations, consumed daily 500 mg theobromine or placebo for 4 weeks. After 4 weeks, FMD, peripheral arterial tonometry (PAT), augmentation index (AIx), pulse wave velocity (PWV), blood pressure (BP) and retinal microvasculature measurements were performed. These measurements were carried out under fasting conditions and 2.5 h after a high-fat mixed meal challenge. RESULTS:4-week theobromine consumption did not change fasting vascular function markers, except for a decrease in central AIx (cAIx, -?1.7 pp, P?=?0.037) and a trend towards smaller venular calibers (-?2 µm, P?=?0.074). Consuming a high-fat mixed meal decreased FMD (0.89 pp, P?=?0.002), reactive hyperemia index (RHI, -?0.30, P?<?0.001), peripheral systolic BP (SBP, -?3 mmHg, P???0.001), peripheral diastolic BP (DBP, -?2 mmHg, P???0.001), central SBP (-?6 mmHg, P???0.001) and central DBP (-?2 mmHg, P???0.001), but increased heart rate (HR, 2 bpm, P?<?0.001). Theobromine did not modify these postprandial effects, but increased postprandially the brachial artery diameter (0.03 cm, P?=?0.015), and decreased the cAIx corrected for a HR of 75 (cAIx75, -?5.0 pp, P?=?0.004) and peripheral AIx (pAIx, -?6.3 pp, P?=?0.017). CONCLUSION:Theobromine consumption did not improve fasting and postprandial endothelial function, but increased postprandial peripheral arterial diameters and decreased the AIx. These findings do not suggest that theobromine alone contributes to the proposed cardioprotective effects of cocoa. This trial was registered on clinicaltrials.gov under study number NCT02209025.